MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/
NICE rejects Janssen’s depression spray Spravato for second timeNICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the Share XNICE rejects Janssen’s depression spray Spravato for second timehttps://pharmaphorum.com/news/nice-rejects/
Digital depression therapy offers hope during COVID-19 pandemicA new digital therapy is aiming to tackle depression during the COVID-19 pandemic, using a brain stimulation headset Share XDigital depression therapy offers hope during COVID-19 pandemichttps://pharmaphorum.com/news/digital-depression-therapy-offers-hope-during-covid-19-pandemic/
Orexo buys US rights to GAIA’s deprexis digital therapeuticSweden’s Orexo has announced it has bought the exclusive US rights to GAIA’s deprexis, a digital therapy to Share XOrexo buys US rights to GAIA’s deprexis digital therapeutichttps://pharmaphorum.com/news/orexo-buys-us-rights-to-gaias-deprexis-digital-therapeutic/
ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKThe top EU court has endorsed an earlier decision by the UK financial regulator to fine GlaxoSmithKline in Share XECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSKhttps://pharmaphorum.com/news/ecj-backs-uk-regulators-pay-for-delay-fine-levied-on-gsk/
NICE rejects J&J’s Spravato for treatment-resistant depressionThe UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal Share XNICE rejects J&J’s Spravato for treatment-resistant depressionhttps://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/
Intra-Cellular ends year with OK for schizophrenia drug lumateperoneUS biotech Intra-Cellular Therapies’ has claimed an FDA approval for schizophrenia therapy lumateperone setting up the launch of Share XIntra-Cellular ends year with OK for schizophrenia drug lumateperonehttps://pharmaphorum.com/news/intra-cellular-ends-year-with-ok-for-schizophrenia-drug-lumateperone/
FDA tags psilocybin drug as clinical depression Breakthrough TherapyThe FDA has tagged psilocybin, the illegal psychoactive compound found in ‘magic mushrooms’, as a potential breakthrough treatment Share XFDA tags psilocybin drug as clinical depression Breakthrough Therapyhttps://pharmaphorum.com/news/fda-tags-psilocybin-drug-as-clinical-depression-breakthrough-therapy/
